We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Hepatic arterial infusion chemotherapy using fluorouracil, epirubicin, and mitomycin C for patients with liver metastases from gastric cancer after treatment failure of systemic S-1 plus cisplatin.
- Authors
Seki, Hiroshi; Ohi, Hiroyuki; Ozaki, Toshirou; Yabusaki, Hiroshi
- Abstract
<bold>Background: </bold>For patients with liver metastases from gastric cancer (LMGC), combination chemotherapy with fluoropyrimidines and platinum agents has been recognized as standard treatment. However, the prognosis of hepatic progression after first-line treatment failure remains poor. When hepatic progression occurs, hepatic arterial infusion (HAI) chemotherapy may be helpful for preventing disease progression.<bold>Purpose: </bold>To retrospectively assess the feasibility and efficacy of HAI chemotherapy using 5-fluorouracil, epirubicin, and mitomycin C (FEM) for patients with LMGC after failure of systemic S-1 plus cisplatin.<bold>Material and Methods: </bold>We reviewed the records of patients who received HAI chemotherapy using FEM for LMGC that progressed during systemic S-1 plus cisplatin treatment while extrahepatic disease was decreased or did not appear. HAI chemotherapy was given as second-line therapy using 5-fluorouracil (330 mg/m(2) weekly), epirubicin (30 or 40 mg/m(2) every 4 weeks), and mitomycin C (2.7 mg/m(2) biweekly).<bold>Results: </bold>Fourteen patients were analyzed. Toxicity of HAI chemotherapy was generally mild. The objective response rate was 42.9%, including a complete response rate of 14.3%. Median times to hepatic and extrahepatic progression were 9.2 and 7.4 months, respectively. Of 12 patients with documented progression after HAI chemotherapy, 10 patients (83.3%) received additional treatment, including irinotecan or taxanes. Overall, median survival was 12.7 months.<bold>Conclusion: </bold>Our findings suggest that HAI chemotherapy using FEM is a feasible and effective treatment for patients with LMGC after failure of systemic S-1 plus cisplatin. HAI chemotherapy employed in the second-line setting is useful for achieving long-term disease control of LMGC.
- Subjects
LIVER metastasis; INFUSION therapy; MITOMYCIN C; FLUOROURACIL; ANTINEOPLASTIC agents; CATHETERS; COMBINATION drug therapy; CISPLATIN; COMPUTED tomography; HEPATIC artery; HETEROCYCLIC compounds; LIVER tumors; STOMACH tumors; SURVIVAL; TREATMENT effectiveness; DISEASE progression; EPIRUBICIN; MITOMYCINS; INTRA-arterial infusions
- Publication
Acta Radiologica, 2016, Vol 57, Issue 7, p781
- ISSN
0284-1851
- Publication type
journal article
- DOI
10.1177/0284185115603247